Grünenthal joins Munich nucleic acid therapeutics cluster

The pharmaceutical company said the CNATM network will support its oligonucleotide research in pain and neurological diseases, including ASOs and siRNA, through ties with German universities and biotech partners.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.